Nine-valent vaccine, which is also known as nine-valent cervical cancer vaccine, is suitable for the age group of 16~26 years old. In China, the nine-valent cervical cancer vaccine is suitable for women between the ages of 16 and 26. This is because the nine-valent vaccine is listed as a clinically urgently needed drug, and the data on the injection of the nine-valent vaccine is adopted from overseas clinical data. Clinical trials have been conducted in women aged 16 to 26 years, and studies have shown that the vaccine has the same protective benefits in the global population as well as in the East Asian Chinese population, and that the benefits outweigh the risks. Of course, the vaccine can be administered over the age of 26, but the lack of research data does not preclude it. It is recommended that the vaccine be administered between the ages of 16 and 26, when protection is more effective. The vaccine should be administered under a doctor’s supervision.